Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics presented updated Phase 1b data for IMA402 PRAME bispecific and Phase 1 data for IMA203CD8 PRAME cell therapy a | Oct 24, 2026 |
| ABT | COURT-RULING | neutral | 1/10 | The court denied a joint stipulation to modify the scheduling order and continue the trial in Rapacon v. Abbott Laborato | Oct 23, 2026 |
| HOTH | DEF 14A | bearish | 6/10 | Rocket One Inc. (HOTH) filed its definitive proxy statement for the 2026 Annual Meeting, seeking shareholder approval on | Oct 23, 2026 |
| BIAF | DEF 14A | neutral | 5/10 | bioAffinity Technologies is holding a special meeting on November 20, 2026, to seek stockholder approval for the issuanc | Oct 23, 2026 |
| ACET | SC 13G | neutral | 3/10 | Daniel Clayton Zedek and Lauren Marie Zedek filed a Schedule 13G on October 23, 2026, disclosing aggregate beneficial ow | Oct 23, 2026 |
| AMGN | COURT-RULING | neutral | 1/10 | The court denied a pro se plaintiff's petition to vacate an arbitration award and granted Amgen's petition to confirm th | Oct 23, 2026 |
| HELP | 3 | neutral | 2/10 | Grant Froese filed a Form 3 initial statement of beneficial ownership, reporting 161,263 common shares (held by spouse a | Oct 23, 2026 |
| HELP | 3 | neutral | 2/10 | Eric Hoskins filed a Form 3 initial statement of beneficial ownership, disclosing 156,000 common shares held by Lucky Sq | Oct 23, 2026 |
| HELP | 3 | neutral | 2/10 | Mark Lawson filed a Form 3 initial statement of beneficial ownership, reporting 3,026 common shares held directly and 15 | Oct 23, 2026 |
| HELP | 3 | neutral | 2/10 | Theresa Firestone filed a Form 3 initial statement of beneficial ownership after becoming a reporting person at Helus Ph | Oct 23, 2026 |
| IONS | 8-K | bullish | 7/10 | Ionis partner Roche announced positive Phase 3 IMAgINATION data for sefaxersen in IgA nephropathy, showing a statistical | Oct 23, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories appointed Mr. Akhil Ravi as Head API and Services and Senior Management Personnel, effective No | Oct 23, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a routine Form 6-K on October 23, 2026, furnishing an intimation letter (Exhibit 99.1) to | Oct 23, 2026 |
| MGNX | 8-K | bullish | 7/10 | MacroGenics reported positive interim Phase 1 data for MGC026, a B7-H3-directed ADC, at ESMO 2026. In heavily pretreated | Oct 23, 2026 |
| IMRN | 6-K | neutral | 3/10 | Immuron Ltd filed a Form 6-K to reduce the remaining capacity under its existing at-the-market (ATM) offering agreement | Oct 23, 2026 |
| CLYM | 8-K | bullish | 7/10 | Climb Bio announced additional Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, at ASN Kidne | Oct 23, 2026 |
| EDSA | 8-K | neutral | 2/10 | Edesa Biotech filed an 8-K on October 23, 2026, reporting that its Board approved substantial increases in the annual ba | Oct 23, 2026 |
| IMRN | 424B5 | neutral | 3/10 | Immuron Ltd filed a 424B5 prospectus supplement to reduce the maximum offering amount under its existing at-the-market ( | Oct 23, 2026 |
| BKHA | 8-K | neutral | 2/10 | Black Hawk Acquisition Corp deposited $150,000 into its trust account to extend the deadline for completing an initial b | Oct 23, 2026 |
| TRAW | 8-K | bearish | 7/10 | Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments, LLC, allowing the company t | Oct 23, 2026 |
| MDCX | 8-K | neutral | 5/10 | Medicus Pharma received a delisting determination letter from Nasdaq on October 20, 2026, after failing to meet the $1.0 | Oct 23, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt sold ~$5.5M in open-market shares on October 22, 2026, following an option exercise, while EVP & G | Oct 23, 2026 |
| TCRT | 8-K | bullish | 5/10 | Alaunos Therapeutics received Nasdaq confirmation that it has regained compliance with the $2.5M minimum stockholders' e | Oct 23, 2026 |
| BIOE | 8-K | neutral | 2/10 | Bio Essence Corp. filed an 8-K reporting the election of Thea Zhang and Geoff Fellows as directors by shareholder writte | Oct 23, 2026 |
| TNYA | DEFA14A | neutral | 4/10 | Tenaya Therapeutics filed a DEFA14A soliciting stockholder approval for a reverse stock split at a ratio between 1-for-1 | Oct 23, 2026 |
| GRDX | 8-K | neutral | 2/10 | GridAI Technologies Corp. filed an 8-K reporting the resignation of board member Manpreet Uppal effective October 19, 20 | Oct 23, 2026 |
| CPIX | 8-K | neutral | 4/10 | Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for s | Oct 23, 2026 |
| RAPP | CLUSTER | bullish | 5/10 | A cluster of insider purchases at Rapport Therapeutics, Inc. (RAPP) shows five directors and the CFO buying a total of ~ | Oct 23, 2026 |
| PVLA | CLUSTER | neutral | 2/10 | Two Palvella insiders, COO Kathleen Goin and Director George Jenkins, sold a combined $310K in open-market shares over a | Oct 23, 2026 |
| APVO | 8-K | neutral | 2/10 | Aptevo Therapeutics filed an 8-K to amend its shareholder rights plan (poison pill), extending the expiration date by on | Oct 23, 2026 |